

REFERRECES

1. UNAIDS. AIDS epidemic update: December 1999: UNAIDS; 2000 Feb-Mar.
2. AVERT. South East Asian HIV&AIDS Statistics. 2004. "Thailand". In; 2004.
3. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science* 1996;272(5265):1167-70.
4. Piatak M, Jr., Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. *Science* 1993;259(5102):1749-54.
5. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. *J Clin Microbiol* 1994;32(2):292-300.
6. Pachl C, Todd JA, Kern DG, Sheridan PJ, Fong SJ, Stempien M, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. *J Acquir Immune Defic Syndr Hum Retrovirol* 1995;8(5):446-54.
7. Kievits T, van Gemen B, van Strijp D, Schukkink R, Dircks M, Adriaanse H, et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. *J Virol Methods* 1991;35(3):273-86.
8. WHO. External review of the health sector response to HIV/AIDS in Thailand: A joint publication of the Ministry of Public Health, Thailand and the World Health Organization, Regional Office for South-East Asia; 2005.
9. Public Health at Risk. Oxfam Briefing Paper 2006.
10. Higuchi I, Nerenberg M, Yoshimine K, Yoshida M, Fukunaga H, Tajima K, et al. Failure to detect HTLV-I by in situ hybridization in the biopsied muscles of viral carriers with polymyositis. *Muscle Nerve* 1992;15(1):43-7.

11. Nurmi J, Ylikoski A, Soukka T, Karp M, Lovgren T. A new label technology for the detection of specific polymerase chain reaction products in a closed tube. *Nucleic Acids Res* 2000;28(8):E28.
12. Phanuphak P, Hanvanich M, Sakulramrung R, Moollaor P, Sitprijia V, Phanthumkosol D. Complement changes in falciparum malaria infection. *Clin Exp Immunol* 1985;59(3):571-6.
13. Weniger BG, Limpakarnjanarat K, Ungchusak K, Thanprasertsuk S, Choopanya K, Vanichseni S, et al. The epidemiology of HIV infection and AIDS in Thailand. *Aids* 1991;5 Suppl 2:S71-85.
14. Ruxrungtham K, Phanuphak P. Update on HIV/AIDS in Thailand. *J Med Assoc Thai* 2001;84 Suppl 1:S1-17.
15. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* 1983;220(4599):868-71.
16. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science* 1984;224(4648):500-3.
17. Simon F, Mauclore P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. *Nat Med* 1998;4(9):1032-7.
18. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. *Nature* 1993;362(6418):355-8.
19. Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza M, Gantt K, et al. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. *Immunol Rev* 1994;140:105-30.
20. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. *J Virol* 1994;68(8):5142-55.
21. Mackewicz CE, Yang LC, Lifson JD, Levy JA. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. *Lancet* 1994;344(8938):1671-3.

22. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. *Science* 1996;271(5247):324-8.
23. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. *N Engl J Med* 1995;332(4):201-8.
24. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. *J Infect Dis* 1996;173(1):60-7.
25. CDC. HIV/AIDS surveillance. Atlanta: Center for Disease Control; 1992.
26. Poli G, Fauci AS. The role of monocyte/macrophages and cytokines in the pathogenesis of HIV infection. *Pathobiology* 1992;60(4):246-51.
27. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. *N Engl J Med* 1996;335(15):1091-8.
28. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med* 1997;126(12):946-54.
29. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. *Nature* 1995;373(6510):117-22.
30. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science* 1996;271(5255):1582-6.
31. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. *N Engl J Med* 1996;334(7):426-31.
32. Dewar RL, Highbarger HC, Sarmiento MD, Todd JA, Vasudevachari MB, Davey RT, Jr., et al. Application of branched DNA signal amplification to

- monitor human immunodeficiency virus type 1 burden in human plasma. *J Infect Dis* 1994;170(5):1172-9.
33. RMS; AMPLICOR/COBAS AMPLICOR HIV-1 MONITOR Test, v1.5 Package Inserts. .
 34. Niesters HG. Quantitation of viral load using real-time amplification techniques. *Methods* 2001;25(4):419-29.
 35. de Baar MP, Janssens W, de Ronde A, Fransen K, Colebunders R, Kestens L, et al. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. *AIDS Res Hum Retroviruses* 2000;16(14):1385-94.
 36. Lin HJ, Pedneault L, Hollinger FB. Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma. *J Clin Microbiol* 1998;36(3):835-9.
 37. Elbeik T, Charlebois E, Nassos P, Kahn J, Hecht FM, Yajko D, et al. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. *J Clin Microbiol* 2000;38(3):1113-20.
 38. Erice A, Brambilla D, Bremer J, Jackson JB, Kokka R, Yen-Lieberman B, et al. Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. *J Clin Microbiol* 2000;38(8):2837-45.
 39. Murphy DG, Cote L, Fauvel M, Rene P, Vincelette J. Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. *J Clin Microbiol* 2000;38(11):4034-41.
 40. Bartlett JA, DeMasi R, Dawson D, Hill A. Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. *J Infect Dis* 1998;178(6):1803-5.

41. Deeks SG, Coleman RL, White R, Pahl C, Schambelan M, Chernoff DN, et al. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. *J Infect Dis* 1997;176(2):514-7.
42. Yen-Lieberman B, Brambilla D, Jackson B, Bremer J, Coombs R, Cronin M, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. *J Clin Microbiol* 1996;34(11):2695-701.
43. Ishiguro T, Saitoh J, Yawata H, Yamagishi H, Iwasaki S, Mitoma Y. Homogeneous quantitative assay of hepatitis C virus RNA by polymerase chain reaction in the presence of a fluorescent intercalater. *Anal Biochem* 1995;229(2):207-13.
44. Tseng SY, Macool D, Elliott V, Tice G, Jackson R, Barbour M, et al. An homogeneous fluorescence polymerase chain reaction assay to identify Salmonella. *Anal Biochem* 1997;245(2):207-12.
45. Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. *Biotechniques* 1998;24(6):954-8, 960, 962.
46. Komurian-Pradel F, Paranhos-Baccala G, Sodoyer M, Chevallier P, Mandrand B, Lotteau V, et al. Quantitation of HCV RNA using real-time PCR and fluorimetry. *J Virol Methods* 2001;95(1-2):111-9.
47. Halford WP. The essential prerequisites for quantitative RT-PCR. *Nat Biotechnol* 1999;17(9):835.
48. Halford WP, Falco VC, Gebhardt BM, Carr DJ. The inherent quantitative capacity of the reverse transcription-polymerase chain reaction. *Anal Biochem* 1999;266(2):181-91.
49. Wetmur JG. DNA probes: applications of the principles of nucleic acid hybridization. *Crit Rev Biochem Mol Biol* 1991;26(3-4):227-59.
50. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. *Anal Biochem* 1997;245(2):154-60.

51. Cardullo RA, Agrawal S, Flores C, Zamecnik PC, Wolf DE. Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer. *Proc Natl Acad Sci U S A* 1988;85(23):8790-4.
52. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. *Biotechniques* 1997;22(1):130-1, 134-8.
53. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. *Biotechniques* 1997;22(1):176-81.
54. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of *Thermus aquaticus* DNA polymerase. *Proc Natl Acad Sci U S A* 1991;88(16):7276-80.
55. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. *Biotechnology (N Y)* 1993;11(9):1026-30.
56. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. *Genome Res* 1996;6(10):995-1001.
57. LightCycler Software, Version 3.5; Roche Molecular Biochemicals. In; 2001.
58. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. *J Mol Diagn* 2001;3(2):55-61.
59. Meuer S, Wittwer, C and Nakagawara, K. Quantification on LightCycler. Heidelberg: Springer Press; 2001.
60. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C(T)}$ Method. *Methods* 2001;25(4):402-8.
61. Tichopad A, Dilger M, Schwarz G, Pfaffl MW. Standardized determination of real-time PCR efficiency from a single reaction set-up. *Nucleic Acids Res* 2003;31(20):e122.

62. Tichopad A, Didier A, Pfaffl MW. Inhibition of real-time RT-PCR quantification due to tissue-specific contaminants. *Mol Cell Probes* 2004;18(1):45-50.
63. Liu W, Saint DA. A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. *Anal Biochem* 2002;302(1):52-9.
64. Liu W, Saint DA. Validation of a quantitative method for real time PCR kinetics. *Biochem Biophys Res Commun* 2002;294(2):347-53.
65. Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. *Aids* 1998;12(16):2193-202.
66. Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. *Aids* 1998;12(13):1619-24.
67. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc Natl Acad Sci U S A* 1997;94(24):13193-7.
68. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science* 1997;278(5341):1295-300.
69. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, Kovacs JA. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. *Lancet* 1999;353(9147):119-20.
70. Notermans DW, Jurriaans S, de Wolf F, Foudraine NA, de Jong JJ, Cavert W, et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with zidovudine, zalcitabine and zalcitabine. Ritonavir/3TC/ZDV Study Group. *Aids* 1998;12(2):167-73.
71. Zazzi M, Romano L, Catucci M, Venturi G, De Milito A, Valensin PE. Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. *J Clin Microbiol* 1999;37(2):333-8.

72. Schroter M, Zollner B, Schafer P, Laufs R, Feucht HH. Quantitative detection of hepatitis C virus RNA by light cycler PCR and comparison with two different PCR assays. J Clin Microbiol 2001;39(2):765-8.
73. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25(2):169-93.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright © by Chiang Mai University
All rights reserved